Table 1.
Characteristics of the study cohort with and without cardiovascular events of myocardial infarction, cardiac death, myocardial revascularisation and fatal or non-fatal stroke
| CVE (n=96) | No CVE (n=1326) | p-Value | |
| Age (years) | 58.54±10.65 | 59.29±9.81 | 0.473 |
| Body mass index (kg/m2) | 26.32±3.07 | 26.22±3.21 | 0.790 |
| Gender, men, % (n) | 70.8 (68) | 70.7 (938) | 0.984 |
| Dyslipidaemia, % (n) | 88.5 (85) | 80.6 (1068) | 0.055 |
| Hypertension, % (n) | 78.1 (75) | 72.9 (966) | 0.265 |
| Current smoking, % (n) | 56.3 (54) | 51.2 (679) | 0.343 |
| Duration of diabetes (years) | 10.24±6.66 | 8.64±6.50 | 0.151 |
| Previous PCI, % (n) | 22.9 (22) | 24.0 (318) | 0.810 |
| Previous CABG, % (n) | 1.0 (1) | 3.4 (45) | 0.208 |
| Family history of CAD, % (n) | 17.7 (17) | 14.8 (195) | 0.224 |
| Systolic blood pressure (mm Hg) | 124.94±14.64 | 127.86±16.41 | 0.117 |
| Diastolic blood pressure (mm Hg) | 74.93±9.12 | 77.01±10.17 | 0.071 |
| Left ventricle ejection fraction (%) | 60.4±10.2 | 63.7±8.0 | <0.001 |
| Total cholesterol (mmol/L) | 4.10±1.16 | 4.10±1.21 | 0.962 |
| HDL-cholesterol (mmol/L) | 0.98±0.28 | 1.03±0.27 | 0.126 |
| LDL-cholesterol (mmol/L) | 2.44±0.99 | 2.46±0.96 | 0.827 |
| Triglycerides (mmol/L) | 1.79 (1.28, 2.53) | 1.56 (1.18, 2.21) | 0.054 |
| Apo A1 (g/L) | 1.36±0.37 | 1.32±0.28 | 0.140 |
| Apo B (g/L) | 0.99±0.34 | 0.94±0.33 | 0.113 |
| HbA1c (%) | 7.89±1.54 | 7.50±1.33 | 0.007 |
| Glucose (mmol/L) | 7.52±2.68 | 7.18±2.28 | 0.155 |
| hs-CRP, mg/L | 1.83 (1.08, 4.47) | 1.54 (0.77, 3.23) | 0.017 |
| Uric acid (µmol/L) | 368.39±96.44 | 340.26±93.36 | 0.005 |
| eGFR (mL/min) | 82.03±24.55 | 80.12±25.58 | 0.471 |
| Fibrinogen (g/L) | 3.52±0.85 | 3.30±0.8 | 0.015 |
| Medication | |||
| Statin, % (n) | 69.8 (67) | 71.9 (953) | 0.707 |
| Aspirin, % (n) | 88.1 (84) | 86.7 (1149) | 0.794 |
| Beta-blocker, % (n) | 52.4 (50) | 48.2 (639) | 0.601 |
| Calcium channel blocker | 11.5 (11) | 20.7 (275) | 0.166 |
| ACEI/ARB | 30.0 (29) | 26.5 (351) | 0.521 |
| OADs, % (n) | 48.9 (47) | 54.3 (720) | 0.296 |
| Insulin, % (n) | 27.1 (26) | 25.8 (342) | 0.813 |
| OADs+insulin, % (n) | 13.5 (13) | 19.9 (264) | 0.215 |
Data are presented as mean ± SD, median (25th, 75th percentiles) or % (n).
p-values <0.05 in bold.
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; Apo, apolipoprotein; CVE, cardiovascular events; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated haemoglobin type A1C; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; OADs, oral antidiabetic drugs.